Janux Therapeutics Rallies Another 10%+ on Reports of a Possible Takeover
$Janux Therapeutics(JANX.US$ rallied more than 10% for the second straight session Thursday as investors continued to bid up the biotech amid a report that the company might be up for sale.
JANX rose 12.1% to $50 a share one day after gaining 11.5% on Wednesday following a Bloomberg News report about the potential sale of the firm, which develops anti-cancer drugs.
The news service cited unnamed sources as saying that Janux is working with a financial adviser to consider options that include a possible sale after receiving takeover interest from larger pharmaceutical firms.
All in, Janux has risen 42.4% since last Friday's close at $35.12.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Director of Financial Content
Former top editor at Seeking Alpha, Fidelity.com, TheStreet.com and UPI.
121Followers
124Following
578Visitors
Follow